Codagenix doses first subject in Phase I intranasal Covid-19 vaccine trial - Clinical Trials Arena

Codagenix, in partnership with the Serum Institute of India, has announced the dosing of the first patient in a Phase I clinical trial of a new intranasal vaccine, CoviLiv, for use as a Covid-19 boost

Codagenix, in partnership with the Serum Institute of India, has announced the dosing of the first patient in a Phase I clinical trial of a new intranasal vaccine, CoviLiv, for use as a Covid-19 boos… [+1884 chars]

full article...